Myelodysplastic syndrome

Childhood Leukemias, Second Edition

Volumn , Issue , 2006, Pages 548-570

  Hasle, Henrik ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84932617082     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511471001.022     Document Type: Chapter

References (237)

1. Passmore, S. J., Hann, I. M., Stiller, C. A., et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood, 1995; 85: 1742-50.
2. Hasle, H., Kerndrup, G., &Jacobsen, B. B. Childhoodmyelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia, 1995; 9: 1569-72.
3. Bader-Meunier, B., Mielot, F., Tchernia, G., et al. Myelodysplastic syndrome in childhood: report of 49 patients from a French multicenter study. Br J Haematol, 1996; 92: 344-50.
4. Groupe Francais de Cytogénétique Hématologique. Fortyfour cases of childhood myelodysplasia with cytogenetics, documented by the Groupe Francais de Cytogénétique Hématologique. Leukemia, 1997; 11: 1478-85.
5. Luna-Fineman, S., Shannon, K. M., Atwater, S. K., et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood, 1999; 93: 459-66.
6. Hasle, H., Wadsworth, L. D., Massing, B. G., McBride, M., & Schultz, K. R. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol, 1999; 106: 1027-32.
7. Lopes, L. F. & Lorand-Metze, I. Childhood myelodysplastic syndromes in a Brazilian population. Pediatr Hematol Oncol, 1999; 16: 347-53.
8. Sasaki, H., Manabe, A., Kojima, S., et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia, 2001; 15: 1713-20.
9. Kardos, G., Baumann, I., Passmore, S. J., et al. Refractory anemia in childhood: a retrospective analysis of 67 cases with particular reference to monosomy 7. Blood, 2003; 102: 1997-2003.
10. Passmore, S. J., Chessells, J. M., Kempski, H., et al. Pediatric MDS and JMML in the UK: a population-based study of incidence and survival. Br J Haematol, 2003; 121: 758-67.
11. Steliarova-Foucher, E., Stiller, C., Lacour, B., & Kaatsch, P. International Classification of Childhood Cancer, thirdedition. Cancer, 2005; 103: 1457-67.
12. Court, D. & Edward, D. G. Monocytic leukaemia in childhood. Arch Dis Child, 1939; 14: 231-44.
13. Pearson, H. A. & Diamond, L. K. Chronic monocytic leukemia in childhood. J Pediatr, 1958; 53: 259-70.
14. Shuster, S., Jones, J. H., &Kilpatrick, G. S. Leukaemia and foetal haemoglobin: a case study. Br Med J, 1960; 2: 1556-8.
15. Humbert, J. R., Hathaway, W. E., Robinson, A., Peakman, D. C., &Githens, J. H. Pre-leukemia in children with a missing bone marrow C chromosome and a myeloproliferative disorder. Br J Haematol, 1971; 21: 705-16.
16. Kleihauer, E. The preleukemic syndromes (hematopoietic dysplasia) in childhood. Eur J Pediatr, 1980; 133: 5-10.
17. Bernard, J. & Schaison, G. Transitory bone marrow failure. A series of 13 preleukemic cases in children. Am J Pediatr Hematol Oncol, 1980; 2: 141-4.
18. Wegelius, R. Bone marrow dysfunctions preceding acute leukemia in children: a clinical study. Leuk Res, 1992; 16: 71-6.
19. Hasle, H., Heim, S., Schroeder, H., et al. Transient pancytopenia preceding acute lymphoblastic leukemia (pre-ALL). Leukemia, 1995; 9: 605-8.
20. Sieff, C. A., Chessells, J. M., Harvey, B. A., Pickthall, V. J., & Lawler, S. D. Monosomy 7 in childhood: a myeloproliferative disorder. Br J Haematol, 1981; 49: 235-49.
21. Weiss, K., Stass, S., Williams, D., et al. Childhood monosomy 7 syndrome: clinical and in vitro studies. Leukemia, 1987; 1: 97-104.
22. Evans, J. P., Czepulkowski, B., Gibbons, B., Swansbury, G. J., & Chessells, J. M. Childhood monosomy 7 revisited. Br J Haematol, 1988; 69: 41-5.
23. Hann, I. M. Myelodysplastic syndromes. Arch Dis Child, 1992; 67: 962-6.
24. Baranger, L., Baruchel, A., Leverger, G., Schaison, G., & Berger, R. Monosomy-7 in childhood hemopoietic disorders. Leukemia, 1990; 4: 345-9.
25. Hasle, H., Aricò, M., Basso, G., et al. Myelodysplastic syndrome, juvenilemyelomonocyticleukemia, andacutemyeloid leukemia associated with complete or partial monosomy 7. Leukemia, 1999; 13: 376-85.
26. Woods, W. G., Barnard, D. R., Alonzo, T. A., et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol, 2002; 20: 434-40.
27. Bennett, J. M., Catovsky, D., Daniel, M. T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol, 1982; 51: 189-99.
28. Bennett, J. M., Catovsky, D., Daniel, M. T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med, 1985; 103: 620-5.
29. Cantù-Rajnoldi, A., Porcelli, P., Cattoretti, G., et al. Myelodysplastic syndromes in children: observation on five cases. Eur Paediatr Haematol Oncol, 1984; 1: 71-5.
30. Wering, E. R. van, Kamps, W. A., Vossen, J. M., List Nuver, C. J. van der, & Theunissen, P. M. Myelodysplastic syndromes in childhood: three case reports. Br J Haematol, 1985; 60: 137-42.
31. Jaffe, E. S., Harris, N. L., Stein, H., &Vardiman, J. W., eds., World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues (Lyon, France: IARC Press, 2001).
32. Emanuel, P. D. Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol, 1999; 105: 852-63.
33. Hasle, H., Niemeyer, C. M., Chessells, J. M., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia, 2003; 17: 277-82.
34. Mandel, K., Dror, Y., Poon, A., & Freedman, M. H. A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. J Pediatr Hematol Oncol, 2002; 24: 596-605.
35. Miyazato, A., Ueno, S., Ohmine, K., et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood, 2001; 98: 422-7.
36. Maarek, O., Jonveaux, P., Le Coniat, M., Derre, J., & Berger, R. Fanconi anemia and bone marrowclonal chromosomeabnormalities. Leukemia, 1996; 10: 1700-4.
37. Blank, J. & Lange, B. Preleukemia in children. J Pediatr, 1981; 98: 565-8.
38. Hasle, H. & Passmore, J. Epidemiology of MDS and myeloproliferative disorders in children. In: Lopes, L. F. & Hasle, H, eds. Myelodysplastic and Myeloproliferative Disorders in Children. (Sao Paulo: Tecmedd e Lemar, 2003).
39. Lie, S. O., Berglund, G., Gustafsson, G., et al. High-dose Ara-C as a single-agent consolidation therapy in childhood acutemyelogenous leukemia. Hamatol Bluttransfus, 1990; 33: 215-21.
40. Woods, W. G., Kobrinsky, N., Buckley, J., et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. J Clin Oncol, 1993; 11: 1448-57.
41. Creutzig, U., Cantù-Rajnoldi, A., Ritter, J., et al. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany. Am J Pediatr Hematol Oncol, 1987; 9: 324-30.
42. Ravindranath, Y., Abella, E., Krischer, J. P., et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience in Pediatric Oncology Group AML Study 8498. Blood, 1992; 80: 2210-4.
43. Wells, R. J., Woods, W. G., Buckley, J. D., et al. Treatment of newly diagnosed children and adolescents with acutemyeloid leukemia: a Children's Cancer Group study. J Clin Oncol, 1994; 12: 2367-77.
44. Brandwein, J. M., Horsman, D. E., Eaves, A. C., et al. Childhood myelodysplasia: suggested classification as myelodysplastic syndromes based on laboratory and clinical findings. Am J Pediatr Hematol Oncol, 1990; 12: 63-70.
45. Tuncer, M. A., Pagliuca, A., Hicsönmez, G., et al. Primary myelodysplastic syndrome in children: clinical experience in 33 cases. Br J Haematol, 1992; 82: 347-53.
46. Hasle, H., Clausen, N., Pedersen, B., & Bendix-Hansen, K. Myelodysplastic syndrome in a child with constitutional trisomy 8 mosaicism and normal phenotype. Cancer Genet Cytogenet, 1995; 79: 79-81.
47. Maserati, E., Aprili, F., Vinante, F., et al. Trisomy 8 inmyelodysplasia and acute leukemia is constitutional in 15-20% of cases. Genes Chromosomes Cancer, 2002; 33: 93-7.
48. Hasle, H. Turner syndrome and myelodysplastic syndrome. No reason to alert. J Pediatr Hematol Oncol, 1997; 19: 179.
49. Butturini, A., Gale, R. P., Verlander, P. C., et al. Hematologic abnormalities in Fanconi anemia: an international Fanconi anemia registry study. Blood, 1994; 84: 1650-5.
50. Auerbach, A. D. & Allen, R. G. Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. Cancer Genet Cytogenet, 1991; 51: 1-12.
51. Alter, B. P., Caruso, J. P., Drachtman, R. A., et al. Fanconi anemia: myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet, 2000; 117: 125-31.
52. Freedman, M. H., Bonilla, M. A., Fier, C., et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood, 2000; 96: 429-36.
53. Tidow, N., Pilz, C., Teichmann, B., et al. Clinical relevance of point mutations in the cytoplasmic domain of the granulocyte colony-stimulating factor receptorgenein patientswithsevere congenital neutropenia. Blood, 1997; 89: 2369-75.
54. Zeidler, C., Welte, K., Barak, Y., et al.Stemcell transplantationin patients with severe congenital neutropenia without evidence of leukemic transformation. Blood, 2000; 95: 1195-8.
55. Smith, O.P. Shwachman-Diamondsyndrome. Semin Hematol, 2002; 39: 95-102.
56. Cunningham, J., Sales, M., Pearce, A., et al. Does isochromosome 7q mandate bone marrow transplant in children with Shwachman-Diamond syndrome? Br J Haematol, 2002; 119: 1062-9.
57. Dijken, P. J. van & Verwijs, W. Diamond-Blackfan anemia and malignancy.Acasereportandareviewoftheliterature. Cancer, 1995; 76: 517-20.
58. Dokal, I. Dyskeratosis congenita in all its forms. Br J Haematol, 2000; 110: 768-79.
59. Socie, G., Henry, Amar, M., Bacigalupo, A., et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. NEngl J Med, 1993; 329: 1152-7.
60. Ohara, A., Kojima, S., Hamajima, N., et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complicationin childrenwithacquiredaplasticanemia. Blood, 1997; 90: 1009-13.
61. Führer, M., Rampf, U., Burdach, S., et al. Immunosuppressive therapy and bone marrowtransplantation for aplastic anemia in children: results of the study SAA 94[abstract]. Blood, 1998; 92: 156a.
62. Führer, M., Burdach, S., Ebell, W., et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Cambridge Books Online (c) Cambridge University Press, 2009 Myelodysplastic syndrome 565 Austrian Pediatric Aplastic Anemia Working Group. Klin Pädiatr, 1998; 210: 173-9.
63. Ohara, A., Kojima, S., Okamura, J., et al. Evolution of myelodysplastic syndromeandacutemyelogenous leukaemia in children with hepatitis-associated aplastic anaemia. Br J Haematol, 2002; 116: 151-4.
64. Locasciulli, A., Arcese, W., Locatelli, F., Di Bona, E., & Bacigalupo, A. Treatment of aplastic anaemia with granulocytecolony stimulating factor and risk of malignancy. Lancet, 2001; 357: 43-4.
65. Kojima, S., Hibi, S., Kosaka, Y., et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood, 2000; 96: 2049-54.
66. Kojima, S., Ohara, A., Tsuchida, M., et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood, 2002; 100: 786-90.
67. Carroll, W. L., Morgan, R., & Glader, B. E. Childhood bone marrow monosomy 7 syndrome: a familial disorder? J Pediatr, 1985; 107: 578-80.
68. Shannon, K. M., Turhan, A. G., Chang, S. S., et al. Familial bone marrow monosomy 7. Evidence that the predisposing locus is not on the long arm of chromosome 7. J Clin Invest, 1989; 4: 984-9.
69. Gilchrist, D. M., Friedman, J. M., Rogers, P. C., &Creighton, S. P. Myelodysplasia and leukemia syndrome with monosomy 7: a genetic perspective. Am J Med Genet, 1990; 35: 437-41.
70. Luna-Fineman, S., Shannon, K. M., & Lange, B. J. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. Blood, 1995; 85: 1985-99.
71. Hasle, H. & Olsen, J. H. Cancer in relatives of children with myelodysplastic syndrome, acute and chronic myeloid leukaemia. Br J Haematol, 1997; 97: 127-31.
72. Mijovic, A., Antunovic, P., Pagliuca, A., & Mufti, G. J. Familial myelodysplastic syndromes: a key to understanding leukaemogenesis? [abstract] Leuk Res, 1997; 21(Suppl. 1): S6.
73. Gao, Q., Horwitz, M., Roulston, D., et al. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer, 2000; 28: 164-72.
74. Hasle, H., Olsen, J. H., Hansen, J., Friedrich, U., & Tommerup, N. Occurrence of cancer in a cohort of 183 persons with constitutional chromosome 7 abnormalities. Cancer Genet Cytogenet, 1998; 105: 39-42.
75. Minelli, A., Maserati, E., Giudici, G., et al. Familial partial monosomy 7 and myelodysplasia. different parental origin of the monosomy 7 suggests action of a mutator gene. Cancer Genet Cytogenet, 2001; 124: 147-51.
76. Pui, C. H., Hancock, M. L., Raimondi, S. C., et al. Myeloid neoplasia in children treated for solid tumours. Lancet, 1990; 336: 417-21.
77. Pui, C. H., Ribeiro, R. C., Hancock, M. L., et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med, 1991; 325: 1682-7.
78. Rubin, C. M., Arthur, D. C., Woods, W. G., et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood, 1991; 78: 2982-8.
79. Hayani, A., Mahoney, D. H. J., & Taylor, L. D. Therapy-related myelodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy. J Neurooncol, 1992; 14: 57-62.
80. Levine, E. G.&Bloomfield, C.D. Leukemias andmyelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol, 1992; 19: 47-84.
81. Pedersen-Bjergaard, J. & Rowley, J. D. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood, 1994; 83: 2780-6.
82. Pedersen-Bjergaard, J., Christiansen, D. H., Andersen, M. K., & Skovby, F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia, 2002; 16: 2177-84.
83. Barnard, D. R., Lange, B., Alonzo, T. A., et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood, 2002; 100: 427-34.
84. Thomsen, J. B., Schroeder, H., Kristinsson, J., et al.Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer, 1999; 86: 1080-6.
85. Davies, S. M. Therapy-related leukemia: is the risk life-long and canwe identify patients at greatest risk? J Pediatr Hematol Oncol, 2000; 22: 302-5.
86. Sasaki, H., Manabe, A., Kojima, S., et al. Myelodysplastic syndromes in childhood: a retrospective study in Japan[abstract]. Leukemia, 2000; 14: 968.
87. Rodriguez-Galindo, C., Poquette, C. A., Marina, N. M., et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol, 2000; 22: 321-9.
88. Tefferi, A., Thibodeau, S. N., & Solberg, L. A. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood, 1990; 75: 1770-3.
89. Lom, K. van, Hagemeijer, A., Smit, E. M. E., et al. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia, 1995; 9: 1818-21.
90. Busque, L. & Gilliland, D. G. X-inactivation analysis in the 1990s: promise and potential problems. Leukemia, 1998; 12: 128-35.
91. Head, D. R. Revised classification of acute myeloid leukemia. Leukemia, 1996; 10: 1826-31.
92. Loeb, L. A. A mutator phenotype in cancer. Cancer Res, 2001; 61: 3230-9.
93. Neubauer, A., Shannon, K., &Liu, E. Mutations of the ras protooncogenes in childhood monosomy 7. Blood, 1991; 77: 594-8.
94. Sheng, X. M., Kawamura, M., Ohnishi, H., et al.Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. Leuk Res, 1997; 21: 697-701.
95. Tamaki, H., Ogawa, H., Ohyashiki, K., et al. The Wilms' tumor gene WT1 is agoodmarker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia, 1999; 13: 393-9.
96. Ruutu, P., Ruutu, T., Repo, H., et al.Defectiveneutrophilmigration in monosomy-7. Blood, 1981; 58: 739-45.
97. Niemeyer, C. M., Aricò, M., Basso, G., et al. Chronic myelomonocyticleukemiainchildhood:aretrospectiveanalysis of 110 cases. Blood, 1997; 89: 3534-43.
98. Hasle, H., Kerndrup, G., Yssing, M., et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia, 1996; 10: 1269-73.
99. Hicsönmez, G., Cetin, M., Yenicesu, I., et al. Evaluation of children with myelodysplastic syndrome: importance of extramedullary disease as a presenting symptom. Leuk Lymphoma, 2001; 42: 665-74.
100. Barnard, D. R., Kalousek, D. K., Wiersma, S. R., et al. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: a report from the Childrens Cancer Group. Leukemia, 1996; 10: 5-12.
101. Cantù-Rajnoldi, A., Fenu, S., Kerndrup, G., et al. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol, 2005; 84: 429-33.
102. Rogge, T. & Niemeyer, C. M. Myelodysplastic syndromes in childhood. Onkologie, 2000; 23: 18-24.
103. Rosati, S., Anastasi, J., & Vardiman, J. Recurring diagnostic problems in the pathology of the myelodysplastic syndromes. Semin Hematol, 1996; 33: 111-26.
104. Hasle, H. Myelodysplastic syndromes in childhood. Classification, epidemiology, and treatment. Leuk Lymphoma, 1994; 13: 11-26.
105. Harbott, J., Haas, O. A., Kerndrup, G., et al. Cytogenetic evaluation of children with MDS and JMML. Results of the European working group of childhood MDS (EWOG-MDS)[abstract]. Leukemia, 2000; 14: 961.
106. Grimwade, D., Walker, H., Oliver, F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998; 92: 2322-33.
107. Martinez-Climent, J. A. & Garćıa-Conde, J. Chromosome rearrangements in childhood acute myeloid leukemias and myelodysplastic syndromes. J Pediatr Hematol Oncol, 1999; 21: 91-102.
108. Jakovleva, K., Ogard, I., Arvidsson, I., et al. Masked monosomy 7 in myelodysplastic syndromes is uncommon and of undetermined clinical significance. Leuk Res, 2001; 25: 197-203.
109. Ketterling, R. P., Wyatt, W. A., Van Wier, S. A., et al. Primary myelodysplastic syndromewith normal cytogenetics: utility of ‘FISH panel testing' and M-FISH. Leuk Res, 2002; 26: 235-40.
110. Woods, W. G., Neudorf, S., Gold, S., et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrowtransplantation, and aggressive chemotherapy in children with acutemyeloid leukemia in remission. Blood, 2001; 97: 56-62.
111. Greenberg, P., Cox, C., Le Beau, M. M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997; 89: 2079-88.
112. Nevill, T. J., Fung, H. C., Shepherd, J. D., et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood, 1998; 92: 1910-7.
113. Chan, G. C. G., Wang, W. C., Raimondi, S. C., et al. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count. Leukemia, 1997; 11: 206-11.
114. Xue, Y., Yu, F., Zhou, Z., et al. Translocation (8;21) in oligoblastic leukemia: is this a true myelodysplastic syndrome? Leuk Res, 1994; 18: 761-5.
115. Taj, A. S., Ross, F. M., Vickers, M., et al. t(8; 21) myelodysplasia, an early presentation of M2 AML. Br J Haematol, 1995; 89: 890-2.
116. Latger-Cannard, V., Buisine, J., Fenneteau, O., et al.Dysgranulopoiesis, lowblast count and t(8; 21): an unusual presentation of t(8; 21)AMLaccording to the WHOclassification: a pediatric experience. Leuk Res, 2001; 25: 1023-4.
117. Stetler-Stevenson, M., Arthur, D. C., Jabbour, N., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood, 2001; 98: 979-87.
118. Maynadie, M., Picard, F., Husson, B., et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood, 2002; 100: 2349-56.
119. Hasle, H., Jacobsen, B. B., & Pedersen, N. T. Myelodysplastic syndromes in childhood: a population based study of nine cases. Br J Haematol, 1992; 81: 495-8.
120. Nair, R., Athale, U. A., Iyer, R. S., et al. Childhoodmyelodysplastic syndromes: clinical features, cytogenetics and prognosis. Indian J Pediatr, 1992; 59: 443-8.
121. Mansoor, A. M., Bharadwaj, T. P., Sethuraman, S., et al. Analysis of karyotype, SCE, and point mutation of RAS oncogene in Indian MDS patients. Cancer Genet Cytogenet, 1993; 65: 12-20.
122. Führer, M., Rampf, U., & Bender-Götze, C. Mean corpuscular volume (MCV) in patients with aplastic anemia does this parameter select patients with clonal disease? A retrospective analysis of data of the SAA944study[abstract]. Leukemia, 2000; 14: 961.
123. Fohlmeister, I., Fischer, R., Mödder, B., Rister, M., & Schaefer, H. E. Aplastic anemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features. J Clin Pathol, 1985; 38: 1218-24.
124. Elghetany, M. T., Hudnall, S. D., & Gardner, F. H. Peripheral blood picture in primary hypocellular refractory anemia and Cambridge Books Online (c) Cambridge University Press, 2009 Myelodysplastic syndrome 567 idiopathic acquired aplastic anemia: an additional tool for differential diagnosis. Haematologica, 1997; 82: 21-4.
125. Baumann, I., Führer, M., Bender-Götze, C., Rogge, T., & Niemeyer, C. M. Histopathological features of hypoplastic myelodysplastic syndromeand comparison with severe aplasticanemiain childhood[abstract]. Leuk Res, 1999; 23(Suppl. 1): S41.
126. Appelbaum, F. R., Barrall, J., Storb, R., et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol, 1987; 15: 1134-9.
127. Mikhailova, N., Sessarego, M., Fugazza, G., et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica, 1996; 81: 418-22.
128. Shinohara, K., Yujiri, T., Kamei, S., et al.Absence of point mutation of N-ras oncogene in bone marrowcells with aplastic anemia. Int J Cell Cloning, 1992; 10: 94-8.
129. Elghetany, M. T., Vyas, S., & Yuoh, G. Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia. Ann Hematol, 1998; 77: 261-4.
130. Hasle, H., Kerndrup, G., Jacobsen, B. B., et al. Chronic parvovirus infection mimicking myelodysplastic syndrome in a child with subclinical immunodeficiency. Am J Pediatr Hematol Oncol, 1994; 16: 329-33.
131. Yarali, N., Duru, F., Sipahi, T., Kara, A., & Tezic, T. Parvovirus B19 infection reminiscent of myelodysplastic syndrome in three children with chronic hemolytic anemia. Pediatr Hematol Oncol, 2000; 17: 475-82.
132. Sandhaus, L. M. & Scudder, R. Hematologic and bone marrow abnormalities in pediatric patients with human immunodeficiency virus (HIV) infection. Pediatr Pathol, 1989; 9: 277-88.
133. Mueller, B. U., Tannenbaum, S., & Pizzo, P. A. Bone marrow aspirates and biopsies in children with human immunodeficiency virus infection. J Pediatr Hematol Oncol, 1996; 18: 266-71.
134. Yarali, N., Fisgin, T., Duru, F., & Kara, A. Myelodysplastic features in visceral leishmaniasis. Am J Hematol, 2002; 71: 191-5.
135. Wollman, M. R., Penchansky, L., &Shekhter Levin, S. Transient 7q-in association with megaloblastic anemia due to dietary folate and vitamin B12 deficiency. J Pediatr Hematol Oncol, 1996; 18: 162-5.
136. Brichard, B., Vermylen, C., Scheiff, J. M., Ninane, J., & Cornu, G. Haematological disturbances during long-term valproate therapy. Eur J Pediatr, 1994; 153: 378-80.
137. Yetgin, S., Ozen, S., Saatci, U., et al. Myelodysplastic features in juvenile rheumatoid arthritis. Am J Hematol, 1997; 54: 166-9.
138. Hinson, D. D., Rogers, Z. R., Hoffman, G.F., et al.Hematological abnormalitiesandcholestatic liver disease intwopatients with mevalonate kinase deficiency. Am J Med Genet, 1998; 78: 408-12.
139. Clatch, R. J., Krigman, H. R., Peters, M. G., & Zutter, M. M. Dysplastic haemopoiesis following orthotopic liver transplantation: comparison with similar changes in HIV infection and primary myelodysplasia. Br J Haematol, 1994; 88: 685-92.
140. Hirose, M., Taguchi, Y., Makimoto, A., et al. New variant of congenital dyserythropoietic anemia with trilineage myelodysplasia. Acta Haematol, 1995; 94: 102-4.
141. Bader-Meunier, B., Rieux-Laucat, F., Croisille, L., et al.Dyserythropoiesis associated with a fas-deficient condition in childhood. Br J Haematol, 2000; 108: 300-4.
142. Bader-Meunier, B., Rötig, A., Mielot, F., et al. Refractory anaemia and mitochondrial cytopathy in childhood. Br J Haematol, 1994; 87: 381-5.
143. Haas, O. A. & Gadner, H. Pathogenesis, biology, and management of myelodysplastic syndromes in children. Semin Hematol, 1996; 33: 225-35.
144. Albitar, M., Manshouri, T., Shen, Y., et al. Myelodysplastic syndrome is not merely "preleukemia". Blood, 2002; 100: 791-8.
145. Webb, D. K. H., Passmore, S. J., Hann, I. M., et al. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990-99. Br J Haematol, 2002; 117: 33-9.
146. Niemeyer, C. M., Duffner, U., Bender-Götze, C., et al. AMLtype intensivechemotherapy prior tostemcell transplantation (SCT) does not improve survival in children and adolescents with primary myelodysplastic syndromes (MDS)[abstract]. Blood, 2000; 96: 521a.
147. Vardiman, J. W., Harris, N. L., & Brunning, R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002; 100: 2292-302.
148. Carroll, A., Civin, C., Schneider, N., et al. The t(1; 22)(p13; q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group study. Blood, 1991; 78: 748-52.
149. Lion, T., Haas, O. A., Harbott, J., et al. The translocation t(1; 22)(p13; q13) is a nonrandom marker specifically associated with acute megakaryocytic leukemia in young children. Blood, 1992; 79: 3325-30.
150. Dastugue, N., Lafage-Pochitaloff, M., Pages, M. P., et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH). Blood, 2002; 100: 618-26.
151. Anderson, J. E., Appelbaum, F. R., Schoch, G., et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood, 1996; 87: 51-8.
152. Anderson, J. F., Gooley, T. A., Schoch, G., et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood, 1997; 89: 2578-85.
153. Hasle, H., Baumann, I., Bergsträsser, E., et al. The International Prognostic Scoring System (IPSS) for childhoodmyelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia, 2004; 18: 2008-14.
154. Stollmann, B., Fonatsch, C., & Havers, W. Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome3abnormalityinchildhoodmyeloproliferative disorders. Br J Haematol, 1985; 60: 183-96.
155. Scheurlen, W., Borkhardt, A., Ritterbach, J., & Huppertz, H. I. Spontaneous hematological remission in a boy with myelodysplastic syndromeandmonosomy7. Leukemia, 1994; 8: 1435-8.
156. Benaim, E., Hvizdala, E. E., Papenhausen, P., &Moscinski, L. C. Spontaneous remission in monosomy 7 myelodysplastic syndrome. Br J Haematol, 1995; 89: 947-8.
157. Mantadakis, E., Shannon, K. M., Singer, D. A., et al. Transient monosomy 7. A case series in children and review of the literature. Cancer, 1999; 85: 2655-61.
158. De Simone, A., Cantu, Rajnoldi A., Sainati, L., et al. Spontaneous remission from RAEBin a child. Leukemia, 2001; 15: 856-7.
159. Bader-Meunier, B., Tchernia, G., Mielot, F., et al. Occurrence of myeloproliferative disorders in patients with Noonan syndrome. J Pediatr, 1997; 130: 885-9.
160. Saunthararajah, Y., Nakamura, R., Nam, J. M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 2002; 100: 1570-4.
161. Steensma, D. P., Dispenzieri, A., More, S. B., Schroeder, G., & Tefferi, A. Antithymocyteglobulinhaslimited efficacyandsubstantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood, 2003; 101: 2156-8.
162. Peters, A. M. J., Baumann, I., Strahm, B., et al. Immunosuppressive therapy for children with refractory anemia[abstract]. Bone Marrow Transplant, 2003; 31(Suppl. 1): S183.
163. Hicsönmez, G., Tuncer, A. M., Sayli, T., et al.High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children withmyelodysplastic syndromes. Hematol Pathol, 1995; 9: 185-93.
164. Creutzig, U., Bender-Götze, C., Ritter, J., et al. The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-T. Leukemia, 1998; 12: 652-9.
165. de Witte, T., Suciu, S., Verhoef, G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood, 2001; 98: 2326-31.
166. Longmore, G., Guinan, E. C., Weinstein, H. J., et al. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol, 1990; 8: 1707-14.
167. Anderson, J. E., Appelbaum, F. R., Fisher, L. D., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood, 1993; 82: 677-81.
168. Anderson, J. E., Anasetti, C., Appelbaum, F. R., et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol, 1996; 93: 59-67.
169. Sutton, L., Chastang, C., Ribaud, P., et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrowtransplantation: a long-termstudy of 71 patients Societe Francaise de Greffe de Moelle. Blood, 1996; 88: 358-65.
170. Castro-Malaspina, H., Harris, R. E., Gajewski, J., et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood, 2002;99:1943-51.
171. Guinan, E. C., Tarbell, N. J., Tantravahi, R., & Weinstein, H. J. Bone marrowtransplantation for children withmyelodysplastic syndromes. Blood, 1989; 73: 619-22.
172. Uderzo, C., Locasciulli, A., Cantù-Rajnoldi, A., et al. Allogeneic bone marrow transplantation for myelodysplastic syndromes of childhood: report of three children with refractory anemia with excess of blasts in transformation and review of the literature. Med Pediatr Oncol, 1993; 21: 43-8.
173. Locatelli, F., Pession, A., Bonetti, F., et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrowtransplantation in children withmyelodysplastic syndromes. Leukemia, 1994; 8: 844-9.
174. Yusuf, U., Frangoul, H. A., Gooley, T. A., et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant, 2004; 33: 805-14
175. Stary, J., Locatelli, F., & Niemeyer, C. M. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant, 2005; 35 (Suppl. 1): S13-16.
176. Rubie, H., Attal, M., Demur, C., et al. Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes. Bone Marrow Transplant, 1994; 13: 759-62.
177. Leahey, A., Friedman, D. L., & Bunin, N. J. Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. Bone Marrow Transplant, 1999; 23: 21-5.
178. Davies, S. M., Wagner, J. E., Defor, T., et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia ormyelodysplasia. Br J Haematol, 1997; 96: 749-56.
179. Hongeng, S., Krance, R. A., Bowman, L. C., et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet, 1997; 350: 767-71.
180. Deeg, H. J., Storer, B., Slattery, J. T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood, 2002; 100: 1201-7.
181. de Witte, T., Hermans, J., Vossen, J., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report onbehalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol, 2000; 110: 620-30.
182. Locatelli, F., Zecca, M., Duffner, U., et al. Busulfan, cyclophosphamide and melphalan as pretransplant conditioning regimen for children with MDS and JMML. Interim analysis of the EWOG-MDS/EBMT prospective study[abstract]. Leukemia, 2000; 14: 971.
183. Sierra, J., Perez, W. S., Rozman, C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood, 2002; 100: 1997-2004.
184. Couban, S., Simpson, D. R., Barnett, M. J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood, 2002; 100: 1525-31.
185. Anderson, J. E., Appelbaum, F. R., Schoch, G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol, 1996; 14: 220-6.
186. Martino, R., Caballero, M. D., Simon, J. A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood, 2002; 100: 2243-5.
187. Strahm, B., Greil, J., Kremens, B., et al. A new conditioning regimen for patients with refractory anemia and congenital disorders[abstract]. Bone Marrow Transplant, 2003; 31(Suppl. 1): S26.
188. Nagatoshi, Y., Okamura, J., Ikuno, Y., Akamatsu, M., & Tasaka, H. Therapeutic trial of intensified conditioning regimen with high-dosecytosine arabinoside, cyclophosphamideandeither total body irradiation or busulfan followed by allogeneic bone marrowtransplantation formyelodysplastic syndromein children. Int J Hematol, 1997; 65: 269-75.
189. Copelan, E. A., Penza, S. L., Elder, P. J., et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant, 2000; 25: 1219-22.
190. Peters, C., Matthes-Martin, S., Fritsch, G., et al. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment. Leukemia, 1999; 13: 2070-8.
191. Okumura, H., Takamatsu, H., & Yoshida, T. Donor leucocyte transfusions for relapse inmyelodyplastic syndromeafter allogeneic bone marrow transplantation. Br J Haematol, 1996; 93: 386-8.
192. Beck, J. F., Klingebiel, T., Kreyenberg, H., et al.Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantationcanbepreventedbydonorlymphocyteinfusion inacritical stage of increasing mixed chimerism. Klin Padiatr, 2002; 214: 201-5.
193. Pui, C. H., Relling, M. V., Rivera, G. K., et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia, 1995; 9: 1990-6.
194. Tsurusawa, M., Manabe, A., Hayashi, Y., et al. Therapy-related myelodysplastic syndromein childhood: a retrospective study of 36 patients in Japan. Leuk Res, 2005; 29: 625-32.
195. Ballen, K. K., Gilliland, D. G., Guinan, E. C., et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant, 1997; 20: 737-43.
196. Yakoub-Agha, I., de La Salmoniere, P., Ribaud, P., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol, 2000; 18: 963-71.
197. Hale, G. A., Heslop, H. E., Bowman, L. C., et al. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant, 1999; 24: 735-9.
198. Niemeyer, C. M., Kontny, H. H., Strahm, B., et al. Stem cell transplantation for children with secondary MDS: report from amulticenter study of the European Working Group of MDS in childhood (EWOG-MDS)[abstract]. Bone Marrow Transplant, 2002; 29(Suppl. 2): S3.
199. Faber, J., Lauener, R., Wick, F., et al. Shwachman-Diamond syndrome: early bone marrow transplantation in a high risk patient and new clues to pathogenesis. Eur J Pediatr, 1999; 158: 995-1000.
200. Hasle, H., Clemmensen, I. H., & Mikkelsen, M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet, 2000; 355: 165-9.
201. Hasle, H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol, 2001; 2: 429-36.
202. Zipursky, A., Brown, E., Christensen, H., Sutherland, R., & Doyle, J. Leukemia and/or myeloproliferative syndrome in neonates with Downsyndrome. Semin Perinatol, 1997; 21: 97-101.
203. Massey, G., Zipursky, A., Doyle, J. J., et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): a Pediatric Oncology Group (POG) study[abstract]. Blood, 2002; 100: 87a.
204. Slayton, W. B., Spangrude, G. J., Chen, Z., Greene, W. F., & Virshup, D. Lineage-specific trisomy 21 in a neonate with resolving transient myeloproliferative syndrome. J Pediatr Hematol Oncol, 2002; 24: 224-6.
205. Wu, S. Q., Loh, K. T., Chen, X. R., Joo, W. J., & Mascarenhas, L. Transient myeloproliferative disorder in a phenotypically normal infant with i(21q) mosaicism. Cancer Genet Cytogenet, 2002; 136: 138-40.
206. Hayashi, Y., Eguchi, M., Sugita, K., et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood, 1988; 72: 15-23.
207. Lange, B. The management of neoplastic disorders of haematopoiesis in children with Downsyndrome. Br J Haematol, 2000; 110: 512-24.
208. Miller, R. W., & Shurin, S. B. Neonatal myeloproliferative disorder in Down syndrome: transient or preleukemic[abstract]? Proc ASPHO, 1994; 3: 24.
209. Lange, B. J., Kobrinsky, N., Barnard, D. R., et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's cancer group studies 2861 and 2891. Blood, 1998; 91: 608-15.
210. Matzke, E., Winkler, K., Grosch, Worner I., et al. Beitrag zur juvenilen chronischen myeloischen Leukämie (jCML) Fallbeschreibungund Verlaufsbeobachtungen bei9Patienten. Klin Pädiatr, 1980; 192: 157-68.
211. Crombet, O. & Svarch, E. Down syndrome and juvenile myelomonocytic leukemia. Pediatr Hematol Oncol, 1999; 16: 181-2.
212. Zipursky, A., Thorner, P., De Harven, E., Christensen, H., & Doyle, J. Myelodysplasiaandacutemegakaryoblasticleukemia in Down's syndrome. Leuk Res, 1994; 18: 163-71.
213. Creutzig, U., Ritter, J., Vormoor, J., et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFMStudy Group. Leukemia, 1996; 10: 1677-86.
214. Gamis, A. S., Alonzo, T. E., Lange, B., Woods, W. G., & Smith, F. O. Acute myelogenous leukemia (AML) in Downs Syndrome (DS) patients: outcome, toxicities, and prognostic factors from the CCG 2891 trial[abstract]. Blood, 2001; 98: 720a.
215. Sato, A., Imaizumi, M., Koizumi, Y., et al. Acute myelogenous leukaemia with t(8; 21) translocation of normal cell origin in mosaic Down's syndrome with isochromosome 21q. Br J Haematol, 1997; 96: 614-16.
216. Litz, C. E., Davies, S., Brunning, R. D., et al. Acute leukemia and the transient myeloproliferative disorder associated with Downsyndrome: morphologic, immunophenotypic and cytogenetic manifestations. Leukemia, 1995; 9: 1432-9.
217. Ferster, A., Verhest, A., Vamos, E., De Maertelaere, E., & Otten, J. Leukemia in a trisomy 21 mosaic: specific involvement of the trisomic cells. Cancer Genet Cytogenet, 1986; 20: 109-13.
218. Simon, J. H., Tebbi, C. K., Freeman, A. I., et al. Acutemegakaryoblastic leukemia associated with mosaic Down's syndrome. Cancer, 1987; 60: 2515-20.
219. Okuda, T., Cai, Z., Yang, S., et al. Expression of a knockedin AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood, 1998; 91: 3134-43.
220. Song, W. J., Sullivan, M. G., Legare, R. D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet, 1999; 23: 166-75.
221. Taketani, T., Taki, T., Takita, J., et al. Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome. Leukemia, 2002; 16: 1866-7.
222. Wechsler, J., Greene, M., McDevitt, M. A., et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet, 2002; 32: 148-52.
223. Ahmed, M., Sternberg, A., Hall, G., et al. Natural history of GATA1 mutations in Down syndrome. Blood, 2004; 103: 2480-9.
224. Rainis, L., Bercovich, D., Strehl, S., et al.Mutations in the exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 2003; 102: 981-6.
225. Zipursky, A., Wang, H., Brown, E. J., &Squire, J. Interphase cytogenetic analysis of in vivodifferentiation in themyelodysplasia of Down syndrome. Blood, 1994; 84: 2278-82.
226. Holt, S. E., Brown, E. J., & Zipursky, A. Telomerase and the benign and malignant megakaryoblastic leukemias of Down syndrome. J Pediatr Hematol Oncol, 2002; 24: 14-17.
227. Kojima, S., Sako, M., Kato, K., et al. An effective chemotherapeutic regimen for acutemyeloid leukemiaandmyelodysplastic syndrome in children with Down's syndrome. Leukemia, 2000; 14: 786-91.
228. Zeller, B., Gustafsson, G., Forestier, E., et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol, 2005; 128: 797-804.
229. Teigler-Schlegel, A., Baumann, I., Creutzig, U., Niemeyer, C., & Harbott, J. Acquired chromosome aberrations in children with Down syndrome andmyelodysplastic syndrome or acute myeloid leukemia. Leukemia, 2000; 14: 966.
230. Trejo, R. M., Aguilera, R. P., Nieto, S., & Kofman, S. A t(1;22) (p13;q13) in four children with acute megakaryoblastic leukemia (M7), two with Down syndrome. Cancer Genet Cytogenet, 2000; 120: 160-2.
231. Bunin, N., Nowell, P. C., Belasco, J., et al. Chromosome7 abnormalities in children with Down syndrome and preleukemia. Cancer Genet Cytogenet, 1991; 54: 119-26.
232. Kounami, S., Aoyagi, N., Tsuno, H., et al. Myelodysplastic syndrome after regression of transient abnormal myelopoiesis in a Down syndromeinfant: different clonal origin? Cancer Genet Cytogenet, 1998; 104: 115-18.
233. Duflos-Delaplace, D., Läı, J. J., Nelken, B., et al. Transient leukemoid disorder in a newborn with Down syndrome followed 19 months later by AML: demonstration of the same structural change in both instances with clonal evolution. Cancer Genet Cytogenet, 1999; 131: 166-71.
234. Lie, S. O., Jonmundsson, G., Mellander, L., et al. A populationbased study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol, 1996; 94: 82-8.
235. Slørdahl, S. H., Smeland, E. B., Holte, H., et al. Leukemic blasts with markers of four cell lineages in Down's syndrome ("Megakaryoblastic leukemia"). Med Pediatr Oncol, 1993; 21: 254-8.
236. Taub, J. W., Huang, X., Matherly, L. H., et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood, 1999; 94: 1393-400.
237. Ge, Y., Jensen, T., James, S. J., et al. High frequency of the 844ins68 cystathionine-beta-synthase gene variant in Down syndrome children with acute myeloid leukemia. Leukemia, 2002; 16: 2339-41.